Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing With 25 mg or 50 mg Daily of REL-1017 in MDD
Clinical trial NCT03051256 · COMPLETED
Trial details
- NCT number
- NCT03051256
- Sponsor
- Relmada Therapeutics, Inc.
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-05-11
- Primary completion
- 2019-07-30
- Enrollment
- 62
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.